The long-term objective is to make CD8 + T cell-mediated immunity effective against fully established solid nonhemopoietic tumors, which represent the majority of human cancers. Experimentally, CD8 + T lymphocytes specific for tumor antigens are essential for effective immunity to most cancers. However, once cancers have grown for a week to several weeks, immunizations usually fail to affect tumor growth even though the mice are clearly immunologically responsive to the tumor antigens presented at a different site. Conceptually, the host develops in the tumor a physical and/or immunological """"""""barrier"""""""" which may prevent access of CD8 + T cells to the tumor or inhibit continuing activation/proliferation/survival of these T cells in the tumor and the development of memory. These mechanisms will be examined using TCR transgenic or normal T cells and mice carrying either transplanted tumor fragments in which the antigenic tumor cells are embedded in normal stroma or late established tumors in which the antigen is induced on the tumor cells by genetic recombination.
Aim 1 determines the mechanism causing the impaired immune response to solid non-metastatic tumors, particularly how normal stroma affects antigen release and how direct and indirect presentation the level of antigen expression, and costimulatory inflammation affects the localization, activation and memory formation of responding T cells.
Aim 2 examines how CD8+ T lymphocytes can be made effective against established solid tumors by counteracting or neutralizing the local barrier. It will be determined (i) whether elimination of a Gr-1 + FcR + IgG-TGF-beta-dependent barrier can influence the induction and effector phase of CD8 + T cell immunity in the tumor-bearing host, (ii) how targeting the c-Kit positive myeloid barrier cell with protein-tyrosine kinase inhibitors such as STI571 may be used to permit entry, proliferation and reactivation of CD8 +T cells leading to the destruction of established solid tumors, (iii) how single chain heterominibodies consisting of the V-region of a syngeneic tumor-specific antibody and a costimulatory molecule, T cell survival factor, or lymphoid neogenesis factor, when localized to established solid tumors, may help to overcome the local barrier in solid tumors. Together, studies should lead to a better understanding of how to make CD8 + T cell-mediated immunity effective against fully established solid nonhemopoietic tumors. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA022677-24A1
Application #
6631099
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Howcroft, Thomas K
Project Start
1978-02-01
Project End
2008-04-30
Budget Start
2003-05-01
Budget End
2004-04-30
Support Year
24
Fiscal Year
2003
Total Cost
$266,875
Indirect Cost
Name
University of Chicago
Department
Pathology
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Kammertoens, Thomas; Friese, Christian; Arina, Ainhoa et al. (2017) Tumour ischaemia by interferon-? resembles physiological blood vessel regression. Nature 545:98-102
Arina, Ainhoa; Karrison, Theodore; Galka, Eva et al. (2017) Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. Cancer Immunol Res 5:127-136
Posey Jr, Avery D; Schwab, Robert D; Boesteanu, Alina C et al. (2016) Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity 44:1444-54
Arina, Ainhoa; Idel, Christian; Hyjek, Elizabeth M et al. (2016) Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc Natl Acad Sci U S A 113:7551-6
Leisegang, Matthias; Engels, Boris; Schreiber, Karin et al. (2016) Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res 22:2734-43
Blankenstein, Thomas; Leisegang, Matthias; Uckert, Wolfgang et al. (2015) Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol 33:112-9
Binder, David C; Schreiber, Hans (2014) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res 74:632; discussion 635
Arina, Ainhoa; Schreiber, Karin; Binder, David C et al. (2014) Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol 192:1286-93
Binder, David C; Engels, Boris; Arina, Ainhoa et al. (2013) Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res 1:123-33
Liu, Rebecca Berlant; Engels, Boris; Schreiber, Karin et al. (2013) IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A 110:8158-63

Showing the most recent 10 out of 75 publications